Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 7, 2015, Pages 1109-1118

  Stephan, Carsten ^a,b   Jung, Monika ^a   Rabenhorst, Silke ^a   Kilic, Ergin ^a   Jung, Klaus ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

Author keywords

Diagnostic validity; microRNAs; PCA3; prostate carcinoma; urine sediment

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 183; MICRORNA 205; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; MIRN183 MICRORNA, HUMAN; MIRN205 MICRORNA, HUMAN; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; DIGITAL RECTAL EXAMINATION; GENE EXPRESSION; GLEASON SCORE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; URINALYSIS; URINE LEVEL; URINE SEDIMENT; BIOPSY; BLOOD; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; STANDARD; URINE;

AGED; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BIOPSY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE STANDARDS;

EID: 84930807728     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-1000     Document Type: Article

References (45)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr. Accessed on 6 October, 2014.
3. Wilt TJ, Scardino PT, Carlsson SV, Basch E. Prostate-specific antigen screening in prostate cancer: perspectives on the evidence. J Natl Cancer Inst 2014;106:dju010.
4. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014;65:1046-55.
5. Bunting PS. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta 2002;315:71-97.
6. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
7. Grubb RL III, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. Br J Urol Int 2008;102:1524-30.
8. Gulati R, Inoue LY, Gore JL, Katcher J, Etzioni R. Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst 2014;106:djt367.
9. Stephan C, Ralla B, Jung K. Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochim Biophys Acta 2014;1846:99-112.
10. Ralla B, Stephan C, Meller S, Dietrich D, Kristiansen G, Jung K. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit Rev Clin Lab Sci 2014;51:200-31.
11. Kelly BD, Miller N, Healy NA, Walsh K, Kerin MJ. A review of expression profiling of circulating microRNAs in men with prostate cancer. Br J Urol Int 2013;111:17-21.
12. Mlcochova H, Hezova R, Stanik M, Slaby O. Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol 2014;32:41-9.
13. Kuner R, Brase JC, Sultmann H, Wuttig D. microRNA biomarkers in body fluids of prostate cancer patients. Methods 2013;59:132-7.
14. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012;106:768-74.
15. Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masia E, Casanova J, et al. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol 2014;192:252-9.
16. Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer 2014;5:182-91.
17. Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, et al. MicroRNA profiling in prostate cancer-the diagnostic potential of urinary miR-205 and miR-214. PLoS One 2013;8:e76994.
18. Leyten GH, Hessels D, Jannink SA, Smit FP, de JH, Cornel EB, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014;65:534-42.
19. Dijkstra S, Mulders PF, Schalken JA. Clinical use of novel urine and blood based prostate cancer biomarkers: a review. Clin Biochem 2014;47:889-96.
20. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003;49:1-6.
21. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-95.
22. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010;126:1166-76.
23. Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 2013;59:280-8.
24. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-92.
25. Wotschofsky Z, Liep J, Meyer H-A, Jung M, Wagner I, Disch AC, et al. Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci 2012;8:1363-74.
26. Jung M, Schaefer A, Steiner I, Kempkensteffen C, Stephan C, Erbersdobler A, et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem 2010;56:998-1006.
27. Schaefer A, Jung M, Miller K, Lein M, Kristiansen G, Erbersdobler A, et al. Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med 2010;42:749-58.
28. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-22.
29. Tao Z, Shen M, Zheng Y, Mao X, Chen Z, Yin Y, et al. PCA3 gene expression in prostate cancer tissue in a Chinese population: quantification by real-time FQ-RT-PCR based on exon 3 of PCA3. Exp Mol Pathol 2010;89:58-62.
30. Bu H, Bormann S, Schafer G, Horninger W, Massoner P, Neeb A, et al. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate 2011;71:575-87.
31. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57:921-7.
32. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I. J Clin Chem Clin Biochem 1983;21:709-20.
33. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
34. Filella X, Gimenez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51:729-39.
35. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
36. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002;29:23-39.
37. Kirschner MB, van ZN, Reid G. Cell-free microRNAs: potential biomarkers in need of standardized reporting. Front Genet 2013;4:56.
38. Lam B, Simkin M, Rgheil N, Haj-Ahmad Y. Revised guidelines for RNA quality assessment for diverse biological sample input. Application Note 2012;47:1-4.
39. Sapre N, Hong MK, Macintyre G, Lewis H, Kowalczyk A, Costello AJ, et al. Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer. PLoS One 2014;9:e91729.
40. Ohl F, Jung M, Xu C, Stephan C, Rabien A, Burkhardt M, et al. Gene expression studies in prostate cancer tissue: which reference gene should be selected J Mol Med 2005;83: 1014-24.
41. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003;95:634-5.
42. Elkin EB, Vickers AJ, Kattan MW. Primer: using decision analysis to improve clinical decision making in urology. Nat Clin Pract Urol 2006;3:439-48.
43. Hessvik NP, Phuyal S, Brech A, Sandvig K, Llorente A. Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim Biophys Acta 2012;1819:1154-63.
44. Schaefer A, Stephan C, Busch J, Yousef GM, Jung K. Diagnostic, prognostic, and therapeutic implications of miRNAs in urologic tumors. Nat Rev Urol 2010;7:286-97.
45. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.